{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T04:33:52Z","timestamp":1719635632626},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1007\/s11914-996-0007-4","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:22:25Z","timestamp":1180131745000},"page":"123-128","source":"Crossref","is-referenced-by-count":10,"title":["Skeletal and nonskeletal effects of raloxifene"],"prefix":"10.1007","volume":"1","author":[{"given":"Oscar","family":"Gluck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maricic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7_CR1","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2000.18.17.3172","volume":"18","author":"CK Osborne","year":"2000","unstructured":"Osborne CK, Zhao H, Fuqua SA: Selective estrogen receptor modulators. Structure, function and clinical use. J Clin Oncol 2000, 18:3172\u20133186.","journal-title":"J Clin Oncol"},{"key":"7_CR2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","volume":"348","author":"BL Riggs","year":"2003","unstructured":"Riggs BL, Hartmann LC: Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003, 348:618\u2013629.","journal-title":"N Engl J Med"},{"key":"7_CR3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","volume":"138","author":"JGM Kuiper","year":"1997","unstructured":"Kuiper JGM, Carlsson B, Grandien K, et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors \u03b1 and \u03b2. Endocrinology 1997, 138:863\u2013870.","journal-title":"Endocrinology"},{"key":"7_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1010019410881","volume":"2","author":"HU Bryant","year":"2001","unstructured":"Bryant HU: Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator. Rev Endocr Metab Disord 2001, 2:129\u2013138.","journal-title":"Rev Endocr Metab Disord"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1210\/endo.140.12.7164","volume":"140","author":"AL Wijayarantne","year":"1999","unstructured":"Wijayarantne AL, Nagel SC, Paige LA, et al.: Comparative analysis of mechanistic differences among antiestrogens. Endocrinology 1999, 140:5828\u20135840.","journal-title":"Endocrinology"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","volume":"295","author":"Y Shang","year":"2002","unstructured":"Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465\u20132468.","journal-title":"Science"},{"key":"7_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1172\/JCI5347","volume":"103","author":"Z Chen","year":"1999","unstructured":"Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al.: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103:401\u2013406.","journal-title":"J Clin Invest"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641\u20131647.","journal-title":"N Engl J Med"},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999, 282:637\u2013645. This trial was pivotal in demonstrating the reduction in the risk for osteoporotic fractures with raloxifene.","journal-title":"JAMA"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137\u20131148.","journal-title":"J Bone Miner Res"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"NH Bjarnason","year":"2001","unstructured":"Bjarnason NH, Sarkar S, Duong T, et al.: Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in post-menopausal osteoporosis. Osteoporos Int 2001, 12:922\u2013930. Early changes in biochemical markers of bone turnover at 6 and 12 months with raloxifene predict vertebral fracture reduction at 36 months.","journal-title":"Osteoporos Int"},{"key":"7_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"S Sarkar","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong M, et al.: Relationships between bone mineral density and vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002, 17:1\u201310. Changes in bone mineral density correlate poorly with raloxifene\u2019s ability to reduce vertebral fracture. Only 4% of the observed fracture reduction with raloxifene can be explained by increases in bone mineral density.","journal-title":"J Bone Miner Res"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, et al.: Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468\u2013489.","journal-title":"Osteoporos Int"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1007\/s001980200068","volume":"13","author":"O Johnell","year":"2002","unstructured":"Johnell O, Kanis J, Black D, et al.: Raloxifene significantly reduces vertebral fracture risk in patients with osteopenia or osteoporosis defined by total hip BMD T-score. Osteoporos Int 2002, 13:S69-S70.","journal-title":"Osteoporos Int"},{"key":"7_CR15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","volume":"162","author":"M Maricic","year":"2002","unstructured":"Maricic M, Adachi J, Meunier P, et al.: Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Int Med 2002, 162:1140\u20131143.","journal-title":"Arch Int Med"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:3609\u20133617.","journal-title":"J Clin Endocrinol Metab"},{"key":"7_CR17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/er.2001-4002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Zytaruk N, et al.: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:524\u2013528.","journal-title":"Endocr Rev"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N","volume":"44","author":"SL Silverman","year":"2001","unstructured":"Silverman SL, Minshall ME, Shen W, et al.: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 2001, 44:2611\u20132619.","journal-title":"Arthritis Rheum"},{"key":"7_CR19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","volume":"87","author":"O Johnell","year":"2002","unstructured":"Johnell O, Scheele WH, Lu Y, et al.: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:985\u2013992.","journal-title":"J Clin Endocrinol Metab"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","volume":"30","author":"SJM Neele","year":"2002","unstructured":"Neele SJM, Evertz R, De Valk-de Roo G, et al.: Effect of 1 year discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002, 30:599\u2013603.","journal-title":"Bone"},{"key":"7_CR21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1067\/mob.2003.21","volume":"188","author":"VP Jackson","year":"2003","unstructured":"Jackson VP, San Martin JA, Secrest RJ, et al.: Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003, 188:389\u2013395.","journal-title":"Am J Obstet Gynecol"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"S Cummings","year":"1999","unstructured":"Cummings S, Eckert S, Krueper K, et al.: The effect of raloxifene or risk of breast cancer in post-menopausal women. Results from the MORE randomized trial. JAMA 1999, 281:2189\u20132197.","journal-title":"JAMA"},{"key":"7_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"JA Cauley","year":"2001","unstructured":"Cauley JA, Norton L, Lippman ME, et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Breast Cancer Res Treat 2001, 65:125\u2013134.","journal-title":"Breast Cancer Res Treat"},{"key":"7_CR24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jama.287.2.216","volume":"287","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Duong T, Kenyon E, et al.: Estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002, 287:216\u2013220. Raloxifene significantly reduced the risk of breast cancer in women with high and low estradiol levels in the MORE trial.","journal-title":"JAMA"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0093-7754(01)90118-6","volume":"28","author":"DL Wickerham","year":"2001","unstructured":"Wickerham DL, Tan-Chiu E: Breast cancer chemoprevention: current status and future directions. Semin Oncol 2001, 28:253\u2013259.","journal-title":"Semin Oncol"},{"key":"7_CR26","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","volume":"279","author":"BW Walsh","year":"1998","unstructured":"Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445\u20131451.","journal-title":"JAMA"},{"key":"7_CR27","first-page":"214","volume":"85","author":"BW Walsh","year":"2000","unstructured":"Walsh BW, Paul S, Wild RA, et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000, 85:214\u2013218.","journal-title":"J Clin Endocrinol Metab"},{"key":"7_CR28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","volume":"287","author":"E Barrett-Conner","year":"2002","unstructured":"Barrett-Conner E, Grady D, Sashegui A, et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002, 287:847\u2013856. In the MORE trial, raloxifene improved cardiovascular outcomes in women at highest risk.","journal-title":"JAMA"},{"key":"7_CR29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0002-9149(02)02835-7","volume":"90","author":"NK Wenger","year":"2002","unstructured":"Wenger NK, Barrett-Connor E, Collins P, et al.: Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 2002, 90:1204\u20131210.","journal-title":"Am J Cardiol"},{"key":"7_CR30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00042192-199906030-00003","volume":"6","author":"GC Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Shen W, et al.: Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999, 6:188\u2013195.","journal-title":"Menopause"},{"key":"7_CR31","first-page":"91","volume":"98","author":"SR Goldstein","year":"2001","unstructured":"Goldstein SR, Neven P, Zhou L, et al.: Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001, 98:91\u201396.","journal-title":"Obstet Gynecol"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(01)01849-0","volume":"76","author":"S Palomba","year":"2001","unstructured":"Palomba S, Sammartino A, Dicarlo C, et al.: Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001, 76:38\u201343.","journal-title":"Fertil Steril"},{"key":"7_CR33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM200104193441604","volume":"344","author":"K Yaffe","year":"2001","unstructured":"Yaffe K, Krueger K, Sarkar S, et al.: Multiple outcomes of raloxifene evaluation investigators. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001, 344:1207\u20131213.","journal-title":"N Engl J Med"},{"key":"7_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0020-7292(02)00350-8","volume":"79","author":"American College of Obsterticians and Gynecologists Committee on Practice Bulletins-Gynecology","year":"2002","unstructured":"American College of Obsterticians and Gynecologists Committee on Practice Bulletins-Gynecology: ACOG practice bulletin. Selective estrogen receptor modulators. Int J Gynaecol Obstet 2002, 79:289\u2013298.","journal-title":"Int J Gynaecol Obstet"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0007-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-996-0007-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0007-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:33:58Z","timestamp":1559435638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-996-0007-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s11914-996-0007-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}